Afnan Al-Sharif1, Maha Jamal1, Ling X Zhang2, Katherine Larson3, Tannin A Schmidt4, Gregory D Jay5, Khaled A Elsaid1. 1. Massachusetts College of Pharmacy and Health Sciences University, Boston. 2. Rhode Island Hospital, Providence. 3. Brown University, Providence, Rhode Island. 4. University of Calgary, Calgary, Alberta, Canada. 5. Rhode Island Hospital and Brown University, Providence, Rhode Island.
Abstract
OBJECTIVE: To evaluate the binding of recombinant human proteoglycan 4 (rhPRG4) to CD44 receptor and its consequences on cytokine-induced synoviocyte proliferation. METHODS: The binding of rhPRG4 to CD44 and competition with high molecular weight (HMW) hyaluronic acid (HA) was evaluated using a direct enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance. Sialidase A and O-glycosidase digestion of rhPRG4 was performed, and CD44 binding was evaluated using ELISA. Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) were stimulated with interleukin-1β (IL-1β) or tumor necrosis factor α (TNFα) for 48 hours in the presence or absence of rhPRG4 or HMW HA at 20, 40, and 80 μg/ml, and cell proliferation was measured. The contribution of CD44 was assessed by coincubation with a CD44 antibody (IM7). The antiproliferative effect of rhPRG4 was investigated following treatment of PRG4(-/-) mouse synoviocytes with IL-1β or TNFα in the presence or absence of IM7. RESULTS: Recombinant human PRG4 bound CD44 and interfered with the binding of HMW HA to CD44. Removal of sialic acid and O-glycosylations significantly increased CD44 binding by rhPRG4 (P < 0.001). Both rhPRG4 and HMW HA at 40 and 80 μg/ml significantly suppressed IL-1β-induced proliferation of RA FLS (P < 0.05). Recombinant human PRG4 at 20, 40, and 80 μg/ml significantly suppressed TNFα-induced RA FLS proliferation (P < 0.05). CD44 neutralization reversed the effect of rhPRG4 on IL-1β- and TNFα-stimulated RA FLS and the effect of HMW HA on IL-1β-stimulated RA FLS. Recombinant human PRG4 inhibited cytokine-induced proliferation of PRG4(-/-) synoviocytes, which could be prevented by blocking CD44. CONCLUSION: PRG4 (lubricin) is a novel putative ligand for CD44 and may control synoviocyte overgrowth in inflammatory arthropathies via a CD44-mediated mechanism.
OBJECTIVE: To evaluate the binding of recombinant humanproteoglycan 4 (rhPRG4) to CD44 receptor and its consequences on cytokine-induced synoviocyte proliferation. METHODS: The binding of rhPRG4 to CD44 and competition with high molecular weight (HMW) hyaluronic acid (HA) was evaluated using a direct enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance. Sialidase A and O-glycosidase digestion of rhPRG4 was performed, and CD44 binding was evaluated using ELISA. Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) were stimulated with interleukin-1β (IL-1β) or tumor necrosis factor α (TNFα) for 48 hours in the presence or absence of rhPRG4 or HMWHA at 20, 40, and 80 μg/ml, and cell proliferation was measured. The contribution of CD44 was assessed by coincubation with a CD44 antibody (IM7). The antiproliferative effect of rhPRG4 was investigated following treatment of PRG4(-/-) mouse synoviocytes with IL-1β or TNFα in the presence or absence of IM7. RESULTS: Recombinant humanPRG4 bound CD44 and interfered with the binding of HMWHA to CD44. Removal of sialic acid and O-glycosylations significantly increased CD44 binding by rhPRG4 (P < 0.001). Both rhPRG4 and HMWHA at 40 and 80 μg/ml significantly suppressed IL-1β-induced proliferation of RA FLS (P < 0.05). Recombinant humanPRG4 at 20, 40, and 80 μg/ml significantly suppressed TNFα-induced RA FLS proliferation (P < 0.05). CD44 neutralization reversed the effect of rhPRG4 on IL-1β- and TNFα-stimulated RA FLS and the effect of HMWHA on IL-1β-stimulated RA FLS. Recombinant humanPRG4 inhibited cytokine-induced proliferation of PRG4(-/-) synoviocytes, which could be prevented by blocking CD44. CONCLUSION:PRG4 (lubricin) is a novel putative ligand for CD44 and may control synoviocyte overgrowth in inflammatory arthropathies via a CD44-mediated mechanism.
Authors: Susanne Fuchs; Berno Dankbar; Gunnar Wildenau; Werner Goetz; Christoph H Lohmann; Carsten O Tibesku Journal: J Orthop Res Date: 2004-07 Impact factor: 3.494
Authors: Z Zheng; S Katoh; Q He; K Oritani; K Miyake; J Lesley; R Hyman; A Hamik; R M Parkhouse; A G Farr; P W Kincade Journal: J Cell Biol Date: 1995-07 Impact factor: 10.539
Authors: Katherine M Larson; Ling Zhang; Khaled A Elsaid; Tannin A Schmidt; Braden C Fleming; Gary J Badger; Gregory D Jay Journal: J Orthop Res Date: 2017-03-02 Impact factor: 3.494
Authors: Nina Kosaric; Waracharee Srifa; Clark A Bonham; Harriet Kiwanuka; Kellen Chen; Britta A Kuehlmann; Zeshaan N Maan; Chikage Noishiki; Matthew H Porteus; Michael T Longaker; Geoffrey C Gurtner Journal: Mol Ther Date: 2020-05-30 Impact factor: 11.454
Authors: Marwa M Qadri; Gregory D Jay; Rennolds S Ostrom; Ling X Zhang; Khaled A Elsaid Journal: Am J Physiol Cell Physiol Date: 2018-06-13 Impact factor: 4.249